IL6 and schizophrenia: In fact, several authors suggest that IL-6 might be a relevant biomarker for poor prognosis in several mental pathologies such as depressive disorders (67) and schizophrenia (68), or in the use of drugs such as cannabis and ketamine (69, 70), which are conditions related to neuronal dysfunction and with similar symptoms to the ones of neurobrucellosis (3–5).